ArticleMolecular cancer therapeutics2022

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.

Sakshi Tomar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.